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Synthesizing Law for Synthetic Biology 
Andrew W. Torrance* 
I.  INTRODUCTION 
In his influential 2005 article Foundations for Engineering 
Biology, Drew Endy, a professor in the Department of 
Bioengineering at Stanford University and “one of synthetic 
biology’s foremost visionaries,”1 described the considerable 
promise and limitations of synthetic biology.2 On the optimistic 
side of the ledger, it had already “been used to manipulate 
information, construct materials, process chemicals, produce 
energy, provide food, and help maintain or enhance human 
health and our environment.”3 However, he also lamented that 
“our ability to quickly and reliably engineer biological systems 
that behave as expected remains quite limited.”4 In the ensuing 
five years, synthetic biology has begun to realize its scientific 
potential and has reached the public consciousness. 
In November 2010, the seventh annual International 
Genetically Engineered Machine (iGEM) competition will be 
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 1. Jon Mooallem, Do-It-Yourself Genetic Engineering, N.Y. TIMES MAG., 
Feb. 14, 2010, at 40, 42. 
 2. Drew Endy, Foundations for Engineering Biology, 438 NATURE 449, 
449 (2005). 
 3. Id. 
 4. Id. 
TORRANCE_MACROS_FINAL (DO NOT DELETE) 6/16/2010  2:16 PM 
630 MINN. J. L. SCI. & TECH. [Vol. 11:2 
 
 
held at the Massachusetts Institute of Technology (MIT).5 It is 
expected that roughly two thousand synthetic biologists, 
organized into two hundred teams from dozens of countries, 
will participate. Starting with identical kits of BioBrick™ 
standard DNA parts (BioBricks), which can be combined in a 
manner analogous to Lego® bricks or even modified, teams will 
compete with each other to create synthetic genes, 
polypeptides, metabolic pathways, cells, and organisms that 
will be eligible for prestigious prizes at these synthetic biology 
Olympics. The Registry of Standard Biological Parts (the 
Registry), hosted by MIT, provides these kits of BioBricks to 
competitors and also requests that teams submit new or 
modified BioBricks back into the Registry.6 Since its inception 
in 2003,7 the Registry has received more than 12,000 DNA 
sequences.8 By comparison, there are only about 20,000 genes 
in the human genome.9 
To illustrate the remarkable progress being made by 
synthetic biology, consider a few of the winning projects at the 
2009 iGEM competition. On November 2, 2009, thousands of 
cheering synthetic biologists—mostly undergraduates with a 
relatively modest formal background in biology—gathered 
inside MIT’s Kresge Hall to watch a combined team of Spanish 
students from the Universitat Politècnica de València and the 
Universitat de València (Team València) present the project 
that carried them to the finals. In a surprising turn of events, 
Team València began performing jumping-jacks on the stage. 
Yet, there was method in their strangeness. Soon, on a giant 
screen behind the team members, a pixilated but recognizable 
human figure appeared on a computer display and began 
mirroring Team València’s calisthenics. However, this was no 
ordinary computer display. It was an LEC, or light emitting 
cell, display. The pixels on the computer screen were composed 
                                                          
 5. See iGEM 2009 Main Page, http://2009.igem.org/Main_Page (last 
visited Jan. 23, 2010) [hereinafter iGEM Main]. 
 6. Welcome to the Registry of Standard Biological Parts, 
http://partsregistry.org/Main_Page (last visited Feb. 4, 2010) [hereinafter 
Welcome]. 
 7. Id. 
 8. Registry of Standard Biological Parts Statistics Snapshot, 
http://partsregistry.org/cgi/partsdb/Statistics.cgi (last visited Feb. 4, 2010) 
[hereinafter Registry]. 
 9. JAMES D. WATSON ET AL., MOLECULAR BIOLOGY OF THE GENE 139 (6th 
ed. 2008). 
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not of electronic or chemical components, but, rather, of living 
cells. As described by Team València, “[e]ngineered yeasts able 
to sense and respond to electrical signals are build [sic] (what 
we call LEC). Thanks to a homemade device these LECs work 
cooperatively in such a way that they are able to reproduce 
images in movement, building up a ‘bio-screen’ for the first time 
in history.”10 Team València had successfully created a living 
computer screen composed of genetically engineered yeast 
capable of responding precisely and efficiently in response to 
human commands effectuated through electrical signals. For 
their efforts, they won top awards in the categories of Best New 
Application Area and Best Experimental Measurement, and 
finished as Second Runner Up for the Grand Prize (that is, the 
Biobrick Trophy).11 
The team that did win the Grand Prize, from Cambridge 
University, United Kingdom,12 also managed a remarkable feat 
of biological engineering by designing and constructing several 
artificial genes that will allow genetically engineered 
eubacteria to detect and report environmental toxins by 
changing color.13 These color sensors work with a “sensitivity 
tuner” to allow reporting-via-color of both the presence of a 
toxin as well as its concentration. They named the eubacterium 
that will carry out this elegant task “E. chromi” (that is, 
chromi—”of color”—rather than coli).14 Team Cambridge also 
won the award for Best Environment Project.15 Rounding out 
the top three teams, the First Runner Up was a team from the 
Universität Heidelberg, Germany,16 which “developed and 
successfully applied a synthesis method for synthetic 
promoters,17 and a strategy for their rational design.”18 
                                                          
 10. iGEM 2009 Team Valencia Home Page, 
http://2009.igem.org/Team:Valencia/home (last visited Jan. 24, 2010). 
 11. iGEM Main, supra note 5. 
 12. Id. 
 13. iGEM 2009 Team Cambridge Project Page, 
http://2009.igem.org/Team:Cambridge/Project (last visited Mar. 7, 2010). 
 14. Id. 
 15. iGEM Main, supra note 5. 
 16. Id. 
 17. Promoters are fundamental regions of DNA that modulate the 
expression of genes (that is, gene function). BENJAMIN LEWIN, GENES IX 860 
(2008) (“A promoter is a region of DNA where RNA polymerase binds to 
initiate transcription.”). 
 18. iGEM 2009 Team Heidelberg Project Page, 
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The fact that these synthetic biological creations were 
designed and built by undergraduate students illustrates the 
power and potential of synthetic biology. Unsurprisingly, 
professional biologists, including academics and other medical 
researchers, as well as commercial enterprises are also using 
synthetic biology to design and develop new genes, gene 
combinations, genomes, metabolic pathways, viruses, cells, and 
organisms. The Registry makes BioBricks available not just to 
participants in the iGEM competition, but to academic research 
laboratories as well.19 Perhaps the most famous of these 
products so far is artemisinin, a drug effective at treating 
malaria. Amyris Biotechnologies has continued the research of 
Jay Keasling, a University of California Berkeley biochemical 
engineering professor, to produce a synthetic platform for 
producing artemisinin.20 To accomplish this, Keasling and his 
research team spliced together several genes from different 
source organisms into the eubacterium E. coli to enhance 
production of artemisinin.21 Using synthetic biology, Keasling 
and his colleagues have “increased the amount of artemisinic 
acid that each cell could produce by a factor of one million, 
bringing down the cost of the drug from as much as ten dollars 
for a course of treatment to less than a dollar.”22 Another 
prominent goal to which synthetic biology is being applied is 
the engineering of a synthetic cellulase enzyme capable of 
efficiently converting cellulose from plant waste into simpler 
sugars that could, in turn, be used in the inexpensive 
production of renewable bio fuels. Both Amyris and another 
biotechnology company, LS9, are currently using synthetic 
biological techniques to pursue this potentially lucrative, and 
socially useful, goal.23 
The growing excitement surrounding the potential of 
synthetic biology has now penetrated the public consciousness. 
                                                          
http://2009.igem.org/Team:Heidelberg/Project (last visited Jan. 18, 2010). 
 19. Welcome, supra note 6. 
 20. Michael Specter, A Life of Its Own, NEW YORKER, Sept. 28, 2009, at 
56, 58. 
 21. Vincent JJ Martin et al., Engineering a Mevalonate Pathway in 
Escherichia Coli for Production of Terpenoids, 21 NATURE BIOTECH. 796, 797 
(2003). 
 22. Specter, supra note 20, at 58. 
 23. See Mooallem, supra note 1, at 42; Amyris - Our Products, 
http://www.amyris.com/index.php?option=com_content&task=view&id=33&Ite
mid=300 (last visited Jan. 29, 2010). 
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Though the field had already achieved considerable scientific 
success and recognition, its public profile attained new heights 
over the past year, as two of the most influential U.S. 
magazines—The New Yorker and The New York Times 
Magazine—both published feature articles about synthetic 
biology within a five-month period.24 
It is easy to understand the field’s appeal. Synthetic 
biology offers an approach to, and technologies for, radically 
altering the meaning of biology, as well as the meaning of 
“alive.” By reimagining biology from the perspective of 
engineers, computer programmers, and hackers, synthetic 
biologists hope to move beyond the strictures imposed on genes, 
cells, and organisms by eons of evolution by natural selection.  
Furthermore, by emphasizing open standards for, and 
relatively free sharing of, biological “parts,” making those parts 
widely available to those both within and outside the biological 
research establishment, and encouraging users of those parts to 
alter, combine, and employ them in novel, unsupervised, and 
unexpected ways, many synthetic biologists hope to create a 
community of open source biology engineers and biohackers 
capable of constructing anything from cellular computers to 
self-constructing wooden houses. 
This article examines how the law may adapt to the 
challenges offered by synthetic biology. Part II provides an 
overview of the science that underpins the field.  Part III 
analyzes how intellectual property law, particularly patent, 
copyright, and trademark law, will accommodate some of the 
unique features spawned by synthetic DNA. Part IV analyzes 
the open innovation25 approach to innovation that has driven 
the development of synthetic biology so significantly, and 
examines a nascent attempt to enshrine open innovation 
values, as well as concerns over biosafety,26 into law. 
II.  SYNTHETIC BIOLOGY 
The current explosion of interest in synthetic biology is the 
culmination of a century of biological efforts to control, change, 
                                                          
 24. Mooallem, supra note 1; Specter, supra note 20. 
 25. Throughout this article, “open innovation” is intended to function as 
an umbrella phrase that includes user, open, and collaborative innovation. 
 26. In this article, “biosafety” is intended to include both biosafety and 
biosecurity. 
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reengineer, and remake living systems at the molecular level.  
From experiments on fruit fly genetics conducted by Thomas 
Hunt Morgan in the “Fly Room” at Columbia University27 in 
the 1910s and 1920s to the elucidation of DNA as a double-
helix of nucleic acids by James D. Watson and Francis Crick in 
1953,28 knowledge of molecular biology and methods for genetic 
manipulation improved at an accelerating pace, finally allowing 
the “engineering” and “programming” of living cells and their 
genomes.  This allowed a conceptual break with the previous, 
largely descriptive, molecular biology, and ushered in a new 
paradigm of genetic manipulation at the molecular level. 
A.  GENETIC ENGINEERING 
In the early 1970s, Stanley N. Cohen, a professor at 
Stanford University School of Medicine, and Herbert Boyer, a 
professor at the University of California, San Francisco, 
developed a technique that revolutionized the field of biology. 
Using a restriction endonuclease, Cohen and Boyer, assisted by 
several colleagues, cut open a DNA plasmid from the 
eubacterium, Escherischia coli, inserted foreign DNA into the 
gap in the plasmid, and then sealed this foreign DNA into the 
E. coli plasmid using DNA ligase.29  Their experiments 
demonstrated that DNA from different sources could be 
deliberately recombined into patterns distinct from those in 
nature.30 
The invention of “recombinant DNA” allowed cells and 
organisms to be genetically engineered.31 In turn, it fostered 
the creation of a new industry: biotechnology. Several years 
after the initial demonstration of genetic engineering by Cohen 
and Boyer, a human gene, somatostatin, was successfully 
spliced into E. coli.32  As Sally Hughes has summarized, genetic 
                                                          
 27. See WATSON, supra note 9, at 12–13. 
 28. See EVELYN FOX KELLER, THE CENTURY OF THE GENE 3 (2000). 
 29. Stanley N. Cohen et al., Construction of Biologically Functional 
Bacterial Plasmids In Vitro, 70 PROC. NAT’L ACAD. SCI. U.S.A. 3240, 3240 
(1973). 
 30. Id. at 3244. 
 31. Sally Smith Hughes, Making Dollars out of DNA: The First Major 
Patent in Biotechnology and the Commercialization of Molecular Biology, 92 
ISIS 541, 542 (2001). 
 32. E.g., Keiichi Itakura et al., Expression in Escherichia Coli of a 
Chemically Synthesized Gene for the Hormone Somatostatin, 198 SCI. 1056, 
1056 (1977). 
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engineering offered “a simple method for isolating and 
amplifying any gene or DNA segment and moving it with 
controlled precision, allowing analysis of gene structure and 
function in simple and complex organisms.”33 This simple 
method has advanced genetic research immensely by allowing 
direct manipulation of and experimentation on genomes. 
Although genetic engineering began as a method for 
introducing a single foreign gene into the natural genome of 
another cell, the techniques it has engendered have grown 
significantly in complexity and in their power to modify 
existing cells and organisms. Within five years of the first 
deliberate recombination of DNA, ambition for the field had 
vaulted towards “the new era of ‘synthetic biology’ where not 
only existing genes are described and analyzed but also new 
gene arrangements can be constructed and evaluated.”34 
Synthetic biology has since moved well beyond this early 
conception of the field as one of rearranging genes. Now the 
field envisions not just the redesign of existing organisms, but 
even the de novo design and “programming” of genes and 
organisms. 
B.  GENETIC PROGRAMMING 
Numerous metaphors have been used to describe gene 
function.  The metaphor most congruent to the goals of 
synthetic biology is the gene as algorithm. In this conception of 
the gene, DNA encodes a set of instructions for carrying out 
functions via biochemistry just as a computer program encodes 
a set of instructions for carrying out functions via electricity. 
Sir Francis Crick, one of the Nobel Prize-winning co-discoverers 
of the specific chemical structure of DNA, observed that “DNA 
makes RNA, RNA makes protein, and proteins make us.”35 
French geneticists François Jacob and Jacques Monod 
established that some genes encode biochemical products that, 
in turn, regulate the expression of other genes.36 They proposed 
that “the genome contains not only a series of blue-prints, but a 
co-ordinated program of protein synthesis and the means of 
                                                          
 33. Smith Hughes, supra note 31, at 542. 
 34. Waclaw Szybalski & Ann Skalka, Nobel Prizes and Restriction 
Enzymes, 4 GENE 181, 181–82 (1978). 
 35. Francis Crick, On Protein Synthesis, 7 SYMP. SOC’Y FOR 
EXPERIMENTAL BIOLOGY 139 (1958). 
 36. E.g., WATSON ET AL., supra note 9, at 561. 
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controlling its execution.”37 James Bonner further elaborated 
this metaphor, suggesting that organisms are constructed and 
maintained by a “master programme constituted in turn of a 
set of subprogrammes or subroutines,”38 each of which, in turn, 
comprises “a list of cellular instructions or commands.”39 
One of the guiding principles of synthetic biology is that 
genes and cells can be programmed like computers. As Arjun 
Bhutkar has described, “A primary objective of this nascent 
research area is to create a programmable microorganism from 
scratch.”40  Pregnant in this description is the bold assumption 
that living organisms are capable of being programmed in a 
manner analogous to programming computers. To be 
programmable like a computer, an organism or cell would 
probably have to possess at least some computer-like 
characteristics, such as relative structural simplicity and 
functional predictability. By contrast, if an organism or cell 
were to exhibit structural complexity or functional 
unpredictability, programming it would be difficult and would 
not tend to yield consistent results. One approach synthetic 
biology takes to ensure programmability is the deliberate 
reengineering of biological parts and systems to make them 
structurally simplified and functionally predictable. 
C.  BIOLOGY AS ENGINEERING 
In 1958, Edward L. Tatum and George W. Beadle won the 
Nobel Prize for Medicine.41 Their research on the fungus 
Neurospora produced strong evidence that each gene controls 
the synthesis of a specific enzyme.42 In his Nobel Prize 
acceptance speech, Tatum suggested a future in which biology 
would move beyond description and experimentation into 
design and manipulation: 
                                                          
 37. François Jacob & Jacques Monod, Genetic Regulatory Mechanisms in 
the Synthesis of Proteins, 3 J. MOLECULAR BIOLOGY 318, 354 (1961). 
 38. JAMES BONNER, THE MOLECULAR BIOLOGY OF DEVELOPMENT 134 
(1965). 
 39. KELLER, supra note 28, at 86. 
 40. Arjun Bhutkar, Synthetic Biology: Navigating the Challenges Ahead, 
J. BIOLAW & BUS., Vol. 8, No. 2, 2005, at 19, 20. 
 41. Edward Tatum - Biography, 
http://nobelprize.org/nobel_prizes/medicine/laureates/1958/tatum-bio.html 
(last visited Feb. 2, 2010). 
 42. WATSON ET AL., supra note 9, at 19. 
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With a more complete understanding of the functioning and 
regulation of gene activity in development and differentiation, these 
processes may be more efficiently controlled and regulated, not only 
to avoid structural or metabolic errors in the developing organism, 
but also to produce better organisms. 
. . . [Understanding the genetic code] may permit the improvement of 
all living organisms by processes which we might call biological 
engineering.43 
The 1970s saw the limited implementation of Tatum’s 
“biological engineering” (or “genetic engineering”), which has 
since flowered into a sophisticated array of molecular biological 
techniques commonly known as “biotechnology.” A group of 
biologists now hope to take biology beyond conventional genetic 
engineering into a future where biology and engineering 
science merge into a new field called “synthetic biology.” 
For biology to give rise to an engineering discipline of 
synthetic biology, ethos, insights, and approaches from 
engineering science may be necessary. First and foremost, 
there exists a fundamental threshold question about the nature 
of biological systems, such as genes, genomes, cells, and 
organisms. Is biology impenetrably complex, unmanageably 
complicated, and essentially unpredictable, or can biological 
systems and their components be understood, manipulated, 
and controlled to an extent sufficient to synthesize artificial 
versions? The latter is a necessary prerequisite for the 
successful adoption of engineering principles to biology and for 
the creation of synthetic biology as an engineering discipline. 
Drew Endy, one of the leading voices advocating synthetic 
biology as a discipline, has portrayed this question as a 
welcome challenge and suggested it can be resolved 
empirically.44  In his 2005 manifesto for synthetic biology, 
Foundations for Engineering Biology, Endy,45 forcefully and 
optimistically outlines the major challenges and future of the 
field.46 If biology is amenable to engineering, then engineering 
science may offer a potentially powerful conceptual approach 
                                                          
 43. Edward Tatum - Nobel Lecture, 
http://nobelprize.org/nobel_prizes/medicine/laureates/1958/tatum-lecture.html 
(last visited Feb. 2, 2010). 
 44. Endy, supra note 2, at 449. 
 45. Stanford University School of Medicine and School of Engineering 
Department of Bioengineering Faculty Page, 
http://bioengineering.stanford.edu/faculty/ (last visited Mar. 7, 2010). 
 46. Endy, supra note 2, at 449–53. 
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necessary to the success of synthetic biology. As summarized by 
Endy, this approach involves at least three general principles: 
(1) standardization, (2) decoupling, and (3) abstraction.47 In the 
biological context, standardization would involve “the 
definition, description and characterization of the basic 
biological parts, as well as standard conditions that support the 
use of parts in combination and overall system operation.”48 
Decoupling would decompose larger tasks into smaller tasks 
more amenable to specialization and discrete completion; for 
example, the design of a metabolic pathway composed of 
multiple genes might be separated from the construction of the 
individual genes and of the whole pathway.49 Abstraction would 
comprise at least two steps: breaking a biological engineering 
problem into hierarchical levels of complexity (“abstraction 
hierarchies”) and redesigning the basic components of 
engineered biological systems to simplify the construction and 
deconstruction of such systems.50 In theory, implementation of 
the engineering science approach could lead to the wide 
availability of standard biological parts that could be combined 
into biological devices, which, in turn, could be used to build 
biological systems.51 Nevertheless, as important as this 
engineering science approach may be, the ethos of open science, 
and a concomitant distaste for intellectual property, represents 
what may be an even more significant influence in the 
development of synthetic biology. 
III.  PROPRIETARY SYNTHETIC BIOLOGY 
Synthetic biology promises to challenge fields beyond 
science and technology. It is sure to unsettle notions of how the 
intellectual property laws should apply to biotechnological 
inventions. Three ways in which synthetic biology may force 
change to legal doctrine are discussed below. First, human-
designed DNA sequences, systems, cells, and organisms may 
avoid criticisms about patents claiming “products of nature.”52 
Second, synthetic DNA sequences may qualify for copyright 
                                                          
 47. Id. at 450–52. 
 48. Id. at 450. 
 49. Id. at 451. 
 50. Id. at 451–52. 
 51. Id. 
 52. E.g., Diamond v. Chakrabarty, 447 U.S. 303, 313 (1980). 
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protection as “original works of authorship fixed in [a] tangible 
medium of expression.”53 Third, synthetic biology may create 
new routes to trademark protection of its resulting products 
and services by enabling the routine inclusion in DNA 
sequences (or other engineered biological structures) of 
distinctive motifs capable of serving as legally effective 
indications of source. 
A.  SYNTHETIC GENE PATENTS 
Judge Learned Hand provided the legal basis for the 
patenting of DNA. At about the same time as the birth of 
modern genetics, Judge Hand decided Parke-Davis & Co. v. H. 
K. Mulford & Co.,54 a case involving purified adrenaline. 
Considering the issue of whether adrenaline—a known 
chemical found in nature—could be patentable subject matter, 
he found that, when the inventor had removed adrenaline 
“from the other gland-tissue in which it was found . . . it 
became for every practical purpose a new thing commercially 
and therapeutically.”55 Thus, Judge Hand concluded, “That was 
a good ground for a patent.”56 By the 1970s, advances in 
biotechnology had allowed the nucleotide sequences of genes to 
be determined. In 1971, the claim element “gene” appeared for 
the first time, in U.S. Patent No. 3,710,511.57 In 1973, the first 
patent issued with “DNA” as a claim element.58 By 1982, 
specific nucleotide sequences coding for specific polypeptides 
(that is, human chorionic somatomammotropin (claim 1) and 
animal growth hormone (claim 4)) had been successfully 
claimed in U.S. Patent No. 4,363,877,59 the first patent 
claiming the nucleotide sequences of genes per se.60 
                                                          
 53. 17 U.S.C. § 102 (2006). 
 54. Parke-Davis & Co. v. H. K. Mulford & Co., 189 F. 95 (C.C.S.D.N.Y. 
1911), aff’d, 196 F. 496 (2d Cir. 1912). 
 55. Id. at 103. 
 56. Id. 
 57. See Procedures for Use of Genic Male Sterility in Production of 
Commercial Hybrid Maize, U.S. Patent No. 3,710,511 (filed Apr. 21, 1971) 
(issued Jan. 16, 1973). 
 58. See Diagnostic Method Utilizing Synthetic Deoxyrilionucleotide 
Oligomer Template, U.S. Patent No. 3,755,086 (filed Feb. 9, 1971) (issued Aug. 
28, 1973). 
 59. See Recombinant DNA Transfer Vectors, U.S. Patent No. 4,363,877 
(filed Apr. 19, 1978) (issued Dec. 14, 1982). 
 60. See Gene Patents and Global Competition Issues, GENETIC 
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After the Diamond v. Chakrabarty decision in 1980,61 
patent applications and issued patents claiming DNA 
sequences increased rapidly.62 Today, patenting DNA 
sequences is routine. The USPTO Utility Examination 
Guidelines state that “[a] patent on a gene covers the isolated 
and purified gene but does not cover the gene as it occurs in 
nature.”63 The phrase “[‘isolated DNA’] or a similar term (e.g., 
‘modified DNA’ or ‘purified DNA’) is widely used to distinguish 
the claimed DNA from its naturally occurring counterpart, i.e., 
genomic DNA encoding [the same polypeptide].”64 Such claims 
are “unquestionably patentable over the corresponding 
products of nature,”65 although they must also satisfy criteria of 
patentability other than being statutory patentable subject 
matter.66 
Despite the longstanding Parke-Davis ruling, some have 
argued that DNA sequences should not constitute patentable 
subject matter because they are derived from natural 
(“genomic”) DNA sequences.67 Synthetic biology allows these 
concerns to be avoided entirely. Genes constructed using 
synthetic biological techniques will have their origins in human 
imagination and will, thus, not be products of nature. Even if 
the courts were to accede to the wishes of those opposing the 
patent eligibility of genes isolated from natural genomic 
sources,68 synthetic genes would remain patentable subject due 
to their non-natural origins. In fact, opposition to gene patents 
as products of nature would incentivize preferential investment 
in research, development, and patenting of synthetic genes. 
                                                          
ENGINEERING & BIOTECH. NEWS, Jan. 1, 2006, available at 
http://www.genengnews.com/articles/chitem.aspx?aid=1163. 
 61. Diamond v. Chakrabarty, 447 U.S. 303 (1980). 
 62. Andrew W. Torrance, Gene Concepts, Gene Talk, and Gene Patents, 11 
MINN. J. L. SCI. & TECH. 157, 178 figs.1 & 2 (2010). 
 63. United States Patent and Trademark Office Utility Examination 
Guidelines, 66 Fed. Reg. 1092, 1093 (Jan. 5, 2001). 
 64. Fish & Richardson P.C., Master Class™:  Biotech Course Materials, 
Vol. 1, pg. I-5 (May 11-12, 2005). 
 65. Fish & Richardson P.C., Master Class™:  Biotech Course Materials, 
Vol. 1, pg. I-5 (May 11-12, 2005). 
 66. See, e.g., In re Fisher, 421 F.3d 1365 (Fed. Cir. 2005). 
 67. See, e.g., Andrew W. Torrance, Patent Rights and Civil Wrongs: The 
ACLU Lawsuit, BIO-IT WORLD, July 2009, available at http://www.bio-
itworld.com/comment/2009/07/06/ACLU-lawsuit.html . 
 68. See, e.g., id. 
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Recent tumult regarding the patentability of isolated 
human genes is likely to raise the prospective value of 
synthetic genes. On May 12, 2009, the American Civil Liberties 
Union (ACLU) filed a lawsuit to challenge the eligibility of 
human genes for patent protection.69  As the complaint stated, 
Every person’s body contains human genes, passed down to each 
individual from his or her parents. These genes determine, in part, 
the structure and function of every human body. This case challenges 
the legality and constitutionality of granting patents over this most 
basic element of every person’s individuality.70 
The patents in question claimed specific mutations in 
tumor suppressor genes BRCA1 (“BRCA1, early onset”) and 
BRCA2 (“BRCA2, early onset”).71 A positive test result for these 
tumor suppressor genes usually show a substantial increase in 
risk of developing breast and ovarian cancers in one’s life.72  On 
March 29, 2010, the court granted the ACLU summary 
judgment that human genes constituted unpatentable subject 
matter.73  The decision from the court was decisive: 
The claims-in-suit directed to “isolated DNA” containing human 
BRCA1/2 gene sequences reflect the USPTO’s practice of granting 
patents on DNA sequences so long as those sequences are claimed in 
the form of “isolated DNA.” This practice is premised on the view that 
DNA should be treated no differently from any other chemical 
compound, and that its purification from the body, using well-known 
techniques, renders it patentable by transforming it into something 
distinctly different in character. Many, however, including scientists 
in the field of molecular biology and genomics, have considered this 
practice a “lawyer’s trick” that circumvents the prohibitions on the 
direct patenting of DNA in our bodies but which, in practice, reaches 
the same result. . .. It is concluded that DNA’s existence in an 
“isolated” form alters neither this fundamental quality of DNA as it 
exists in the body nor the information it encodes. Therefore, the 
patents at issue directed to “isolated DNA” containing sequences 
found in nature are unsustainable as a matter of law and are deemed 
unpatentable subject matter under 35U.S.C.§101.74 
Myriad Genetics is highly likely to appeal this decision to 
the Federal Circuit, with strong support from the many 
                                                          
 69. Complaint, Ass’n for Molecular Pathology v. U.S. Patent and 
Trademark Office, 2010 WL 1233416 (S.D.N.Y. 2010) (No. 09 Civ. 4515). 
 70. Id. at 1. 
 71. Id. at 2. 
 72. BRACAnalysis, Frequently Asked Questions, 
http://www.bracnow.com/faqs/#50 (last visited May 13, 2010). 
 73. Ass’n for Molecular Pathology v. U.S. Patent and Trademark Office, 
No. 09 Civ. 4515, 2010 WL 1233416, at *51 (S.D.N.Y. Mar. 29, 2010). 
 74. Id. at *2. 
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companies, universities, and other institutions who own 
potentially valuable gene patents. A further appeal to the U.S. 
Supreme Court is also likely, given the economic and public 
health importance of this issue. What is certain is that this 
stunning court decision has focused intense interest on the 
potential synthetic biology holds for designing genes unlike 
those “found in nature.”  The promise of synthetic biology 
represents an important new pathway to obtaining patent 
rights that successfully claim DNA. 
B.  SYNTHETIC GENE COPYRIGHTS 
A number of previous authors have discussed the 
applicability of copyright law to DNA sequences.75 However, 
none of these discussions were written with the benefit of 
considering the recent explosion in the field of synthetic 
biology. Even so, none of these authors conclusively reject the 
copyrighting of DNA sequences. In light of how plausible these 
authors appear to consider the copyrightability of non-synthetic 
DNA, the case favoring copyrightability of synthetic DNA is a 
fortiori. 
Copyright protection applies to “original works of 
authorship fixed in any tangible medium of expression, now 
known or later developed, from which they can be perceived, 
reproduced, or otherwise communicated, either directly or with 
the aid of a machine or device.”76 Fixation can occur in any 
“form, manner, or medium.”77 However, the mode of fixation 
must be “sufficiently permanent or stable to permit it to be 
perceived, reproduced, or otherwise communicated for a period 
of more than a transitory duration.”78 Since DNA is composed 
                                                          
 75. E.g., Tani Chen, Can a Biological Sequence Be Copyrighted?, INTELL. 
PROP. & TECH. J., Mar. 2007, at 1; Duncan M. Davidson, Common Law, 
Uncommon Software, 47 U. PITT. L. REV. 1037, 1104–05 (1986); Irving Kayton, 
Copyright in Living Genetically Engineered Works, 50 GEO. WASH. L. REV. 191 
(1982); Donna Smith, Comment, Copyright Protection for the Intellectual 
Property Rights to Recombinant Deoxyribonucleic Acid: A Proposal, 19 ST. 
MARY’S L.J. 1083, 1096–1108 (1988); James G. Silva, Copyright Protection of 
Biotechnology Works: Into the Dustbin of History?, B.C. INTELL. PROP. & TECH. 
F., Jan. 28, 2000, 
http://www.bc.edu/bc_org/avp/law/st_org/iptf/articles/content/2000012801.html
. 
 76. 17 U.S.C. § 102 (2006). 
 77. H.R. REP. NO. 94-1476, at 52 (1976). 
 78. 17 U.S.C. § 101 (2006). 
TORRANCE_MACROS_FINAL (DO NOT DELETE) 6/16/2010  2:16 PM 
2010] SYNTHESIZING LAW FOR SYNTHETIC BIOLOGY 643 
 
of stable chemical nucleotides, DNA sequences should easily 
meet this requirement. Furthermore, DNA possesses definite 
sequences of nucleotides that can easily be determined,79 copies 
of DNA may be synthesized routinely and in effectively 
unlimited quantities,80 and molecular DNA has been known to 
last for at least many thousands of years with its nucleotide 
sequence intact.81 The authorship requirement might pose a 
barrier to the copyrightability of genes and other DNA 
sequences derived entirely from natural genomes. A challenge 
would be posed by 17 U.S.C. §102, which provides that 
“[c]opyright protection subsists . . . in original works of 
authorship.”82 By analogy, someone other than the author could 
not claim copyright protection for a preexisting manuscript 
simply by discovering its existence.83 However, synthetic 
biology can involve the design and construction of new, human-
designed DNA sequences. Here the synthetic biologist designs 
the particular DNA sequence, and “writes” it when she 
synthesizes the sequence.84 Since there is an author in this 
case, such DNA sequences should qualify as “original works of 
authorship.” Furthermore, although DNA sequences lack the 
explicit statutory recognition as copyrightable subject matter 
that computer software possesses, synthetic DNA sequences 
may be eligible for copyright protection under the expansive 
interpretation of “works of authorship” manifested by Congress 
in the legislative history of the 1976 amendments to the 
Copyright Act.85 Finally, DNA sequences can be “perceived, 
                                                          
 79. See, e.g., F. Sanger et al., DNA Sequencing with Chain-Terminating 
Inhibitors, 74 PROC. NAT’L ACAD. SCI. U.S.A. 5463 (1977). 
 80. See, e.g., 2 JOSEPH SAMBROOK & DAVID W. RUSSELL, MOLECULAR 
CLONING: A LABORATORY MANUAL 8.4 (3d ed. 2001). 
 81. See, e.g., Eske Willerslev & Alan Cooper, Ancient DNA, 272 PROC. R. 
SOC’Y B 3, 3–5 (2005). 
 82. 17 U.S.C. § 102 (2006). 
 83. Of course, non-authors may obtain copyright protection through 
contractual means for works authored by others. 
 84. In fact, fixing a DNA sequence via more conventional tangible forms of 
expression, such as writing the nucleotide sequence down on paper, may also 
suffice. 
 85. See H.R. REP. NO. 94-1476, at 51 (1976) (“The history of copyright law 
has been one of gradual expansion in the types of works accorded protection, 
and the subject matter affected by this expansion has fallen into two general 
categories. In the first, scientific discoveries and technological developments 
have made possible new forms of creative expression that never existed before. 
In some of these cases the new expressive forms—electronic music, filmstrips, 
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reproduced, or otherwise communicated, either directly or with 
the aid of a machine or device.”86 The genetic code of DNA is 
well understood by biologists. DNA sequences are easily 
reproduced.87 And, machines and routine laboratory methods 
allow the specific nucleotides in DNA sequences to be 
determined.88 
There is no explicit mention of DNA sequences in 17 U.S.C. 
§ 102, nor do any of the eight enumerated categories of 
copyrightable subject matter obviously include DNA sequences. 
There are, however, several significant respects in which DNA, 
genes, arrays of genes, and genomes (not to mention their RNA 
and polypeptide products) fit within the “literary works” 
category,89 both generally and as computer programs. Like the 
English alphabet of twenty-six letters, DNA is composed of an 
alphabet of four nucleotide “letters”: A, T, G, and C.90 Triplets 
of these nucleotide letters form “codons” that correspond to 
specific amino acids. When strung together in a linear chain, 
amino acids comprise polypeptides. A synthetic biologist can 
“write” strings of nucleotides (for example, genes) in any 
pattern she wishes. Some patterns of nucleotide letters could be 
written to produce specifically desired linear chains of amino 
acids. At a higher level of organization, a synthetic biologist 
could compose arrays of multiple synthetic genes in particular 
patterns to produce complex results inside and outside cells. 
Literary works are defined in § 101 as “works . . . expressed in 
words, numbers, or other verbal or numerical symbols or 
indicia, regardless of the nature of the material objects . . . in 
which they are embodied.”91 Nucleotides, DNA, RNA, genes, 
amino acids, polypeptides, and proteins are certainly “indicia,” 
and the letters used to denote nucleotides and amino acids, as 
well as the codes used to denote genes may also qualify as 
“verbal . . . symbols.”  Furthermore, the statement “regardless 
                                                          
and computer programs, for example—could be regarded as an extension of 
copyrightable subject matter Congress had already intended to protect, and 
were thus considered copyrightable from the outset without the need of new 
legislation.”). 
 86. 17 U.S.C. § 102. 
 87. See, e.g., SAMBROOK & RUSSELL, supra note 80, at 8.4–8.17. 
 88. See, e.g., Sanger et al., supra note 79, at 5463. 
 89. 17 U.S.C. § 102. 
 90. A similar molecule, RNA, is composed of adenine, uracil (instead of 
thymine), guanine, and cytosine. The RNA alphabet is A, U, G, and C. 
 91. 17 U.S.C. § 101 (2006). 
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of the nature of the material objects . . . in which they are 
embodied”92 could certainly include DNA or its related 
molecules. 
Section 102 does not restrict eligibility for copyright 
protection only to the seven enumerated categories. Rather, the 
section introduces the enumerated categories with the phrase 
“include[s] the following categories.”93 In the “Definitions” 
section of the Copyright Act,  § 101 explains that 
“including . . . [is] illustrative and not limitative.”94  The House 
Report accompanying the 1976 Copyright Act reinforce this 
broad interpretation: 
The use of the word “include,” as defined in section 101, makes clear 
that the listing is “illustrative and not limitative,” and that the seven 
categories do not necessarily exhaust the scope of “original works of 
authorship” that the bill is intended to protect. Rather, the list sets 
out the general area of copyrightable subject matter, but with 
sufficient flexibility to free the courts from rigid or outmoded concepts 
of the scope of particular categories.95 
When considered in conjunction with the expansive phrase 
in § 102, “any tangible medium of expression, now known or 
later developed,”96 synthetic DNA sequences fit comfortably 
within the category of “literary works.”97 
In 1974, the National Commission on New Technological 
Uses of Copyrighted Works (CONTU) issued a report 
concluding that “computer programs, to the extent that they 
embody an author’s original creation, are proper subject matter 
of copyright.”98 The CONTU was careful to distinguish 
copyrightable subject matter, such as creative expression in 
computer software, from uncopyrightable subject matter, such 
as “ideas, procedures, processes, systems, methods of operation, 
concepts, principles, or discoveries.”99 Moreover, it emphasized 
that “one is always free to make the machine do the same thing 
as it would if it had the copyrighted work placed in it, but only 
                                                          
 92. 17 U.S.C. § 101 (2006). 
 93. 17 U.S.C. § 102. 
 94. 17 U.S.C. § 101. 
 95. See H.R. REP. NO. 94-1476, at 53 (1976). 
 96. 17 U.S.C. § 102. 
 97. Id. 
 98. NAT’L COMM’N ON NEW TECHNOLOGICAL USES OF COPYRIGHTED 
WORKS, FINAL REPORT OF THE NAT’L COMM’N ON NEW TECHNOLOGICAL USES 
OF COPYRIGHTED WORKS 1 (1978) [hereinafter NAT’L COMM’N]. 
 99. Id. at 18 (citing 17 U.S.C. § 102 (b)). 
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by one’s own creative effort rather than by piracy.”100 Formal 
recognition of computer software as copyrightable subject 
matter occurred in 1980, when Title 17 (the “Copyright Act”) 
was amended to include explicit copyright protection for 
computer software.101 Section 101 of the Copyright Act defines 
“computer program” as “a set of statements or instructions to 
be used directly or indirectly in a computer in order to bring 
about a certain result.”102 Although there are some special 
limitations on the exclusive rights conferred to owners of 
copyrights on computer software,103 this form of expression is 
now routinely protected by copyright. 
Synthetic biology is largely based on a conception of genes, 
cells, and organisms as programmable. In a measured version 
of this conception, Endy has suggested that “synthetic biology 
provides an opportunity to test the hypothesis that the 
genomes encoding natural biological systems can be ‘re-
written,’ producing engineered surrogates that might usefully 
supplant some natural biological systems.”104 However, as a 
more ambitious articulation has portrayed it, “[a] primary 
objective of [synthetic biology] is to create a programmable 
microorganism from scratch,” 105 and it is increasingly possible 
to “program living organisms in the same way a computer 
scientist can program a computer.”106 Consequently, if 
computer software is copyrightable, perhaps “biological 
software” is, or ought to be, as well. 
It is relatively easy for a human mind to understand the 
“meaning” of a DNA sequence. Once a proper reading frame 
has been determined for the sequence,107 one only has to 
recognize triplets of nucleotides and assign corresponding 
                                                          
 100. NAT’L COMM’N, supra note 98, at 21. 
 101. See H.R. REP. NO. 96-1307, pt. 1, at 23–24 (1980). 
 102. 17 U.S.C. § 101 (2006). 
 103. 17 U.S.C. § 117 (2006). 
 104. Endy, supra note 2, at 449. 
 105. Bhutkar, supra note 40, at 20. 
 106. The BioBricks Foundation, http://bbf.openwetware.org/ (last visited 
Jan. 7, 2010). 
 107. LEWIN, supra note 17, at 860 (“A reading frame is one of three possible 
ways of reading a nucleotide sequence. Each reading frame divides the 
sequence into a series of successive triplets. There are three possible reading 
frames in any sequence, depending on the starting point. If the first frame 
starts at position 1, the second frame starts at position 2, and the third frame 
starts at position 3.”). 
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amino acids to each triplet. Thus, someone of modest skill in 
genetics could examine a DNA sequence of 300 coding 
nucleotides, in proper reading frame, and then determine the 
specific 100 amino acid sequence of its corresponding 
polypeptide. By contrast, it is much more difficult for one of 
similar skill in computer software to understand the “meaning” 
of either object code or source code. With respect to computer 
software, both source code and object code are eligible for 
copyright protection.108 Source code is a form of a computer 
program expressed in a programming language understandable 
to humans. Object code, by contrast, is a form of a computer 
program expressed in binary (that is, “1s” and “0s”); object code 
cannot generally be understood by the human mind. If object 
code is eligible for copyright protection, then, a fortiori, so 
should DNA sequences, which can be relatively easily 
understood. 
Rather than portray DNA sequences as analogous to 
computer software, a synthetic biologist might consider DNA 
sequences actually to be a form of computer software. A gene is 
a set of instructions for producing a polypeptide.109 A cell (or 
even an organism), via the molecules, metabolic pathways, and 
signaling pathways it contains, acts in response to the set of 
instructions encoded in its genes to carry out a certain result. 
Thus, “a [gene encodes a] set of statements or instructions to be 
used directly or indirectly in a [cellular] computer in order to 
bring about a certain [metabolic or signaling] result.”110 Given 
that one of the primary goals of synthetic biology is to engineer 
cells and genes to become ever more like computers and 
computer software, as synthetic biology succeeds in making 
DNA appear more similar to computer software, DNA 
sequences will likely move towards copyrightability by analogy 
to computer software. Alternatively, if cells and organisms are 
already computers and genes are already software, then DNA 
sequences are already eligible for copyright protection. 
Whether or not cells are computers and genes are 
computer software is largely an empirical question. Endy offers 
                                                          
 108. E.g., Apple Computer, Inc. v. Franklin Computer Corp., 714 F.2d 
1240, 1248 (3d Cir. 1983), cert. dismissed, 464 U.S. 1033 (1984). 
 109. LEWIN, supra note 17, at 852 (“A gene is the segment of DNA 
specifying a polypeptide chain . . . .”). 
 110. Cf. 17 U.S.C. § 101 (2006). The bracketed material is added to show 
how DNA sequences can fit into the existing definition of computer software. 
TORRANCE_MACROS_FINAL (DO NOT DELETE) 6/16/2010  2:16 PM 
648 MINN. J. L. SCI. & TECH. [Vol. 11:2 
 
 
a number of examples, including: 
[a] DNA sequence that programmes a biofilm to take a photograph 
and perform distributed edge-detection on the light-encoded image . . . 
[a] DNA sequence that programmes any mammalian cell to count up 
to 256 in response to a generic input signal . . . [and a] DNA sequence 
that programmes any prokaryote to produce 25 gl-1 artemisinic 
acid.111 
However, rather than characterizing any of these examples 
as science fiction or hopeful thinking, Endy notes that “each 
application is physically plausible, or is the direct extension of 
an already demonstrated result.”112 This suggests that 
synthetic biology is well on the way towards cells as computers 
and genes as computer software. The consequences for the 
copyrightability of synthetic DNA sequences are significant. 
Copyright law limits protection to works of authorship that 
do not monopolize a particular function.113 If a DNA sequence 
of a synthetic gene were to represent the only way of producing 
an RNA or polypeptide with a particular function, then that 
sequence would not likely possess strong copyright protection. 
However, if multiple DNA sequences could produce the RNA or 
polypeptide with a particular function, then any one individual 
sequence would likely have much stronger copyright protection. 
In addition, as long as a work of authorship is original, it 
cannot infringe the copyright of another work of authorship, 
even if the two works of authorship are identical. Thus, even a 
copyright protecting a particular synthetic DNA sequence 
would not prevent others from independently designing an 
identical or similar DNA sequence. In other words, independent 
invention of identical or similar synthetic DNA sequences 
would act as a counterbalance to any monopoly rights conferred 
on the first author. Copying would still constitute copyright 
infringement, but independent invention would be permissible. 
This would stand in stark contrast to the rights conferred by 
patents claiming DNA sequences because the strict liability 
regime of patent law does not relieve independent inventors 
from liability. 
                                                          
 111. Endy, supra note 2, at 449. 
 112. Id. 
 113. See 2 MELVILLE B. NIMMER & DAVID NIMMER, NIMMER ON COPYRIGHT 
§ 2.01[A] (Matthew Bender, rev. ed., 2009). 
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C.  SYNTHETIC GENE TRADEMARKS 
One of the technologies that enables synthetic biology is 
DNA synthesis.114 It is technically routine, rapid, and 
increasingly inexpensive to design a DNA sequence de novo and 
then construct it nucleotide by nucleotide.115 Numerous 
companies offer DNA synthesis as a service.116 Research into 
“DNA printers” has already achieved notable technical 
successes.117 Machines for synthesizing custom DNA with high-
fidelity are likely to become standard equipment in biological 
laboratories (and perhaps even beyond) in the near future. In 
addition to its many more scientific applications, DNA 
synthesis allows one to design patterns or motifs within a 
strand of DNA capable of serving as an indicator of source. 
One of the purposes of a trademark or servicemark is to 
alert consumers as to the source of the goods or services to 
which the mark is connected.118 Furthermore, “[b]y identifying 
the source of the goods, [trademarks] convey valuable 
information to consumers at lower costs.”119 The Lanham Act 
defines “trademark” expansively as “includ[ing] any word, 
name, symbol, or device, or any combination thereof.”120 The 
Supreme Court has interpreted the Lanham Act as describing 
“the universe of things that can qualify as a trademark . . . in 
the broadest terms.”121 The Court has stated, however, that 
“[t]he functionality doctrine prevents trademark law, which 
seeks to promote competition by protecting a firm’s reputation, 
from instead inhibiting legitimate competition by allowing a 
producer to control a useful product feature.”122 
                                                          
 114. This process is sometimes referred to alternatively as “gene 
synthesis.” 
 115. Mark Welch et al., Design Parameters To Control Synthetic Gene 
Expression in Escherichia Coli, PLOS ONE, Sept. 2009, at 1, 1. 
 116. E.g., GENEART, http://geneart.com/english/index.html (last visited 
January 26, 2010); GenScript USA Inc., http://genscript.com (last visited Jan. 
26, 2010). 
 117. E.g.,  Yoshihide Hayashizaki & Jun Kawai, A New Approach to the 
Distribution and Storage of Genetic Resources, 5 NATURE REVS. GENETICS 223, 
223 (2004). 
 118. S. REP. NO. 79-1333, at 3 (1946). 
 119. Scandia Down Corp. v. Euroquilt, Inc., 772 F.2d 1423, 1429 (7th Cir. 
1985), cert. denied, 475 U.S. 1147 (1986). 
 120. Lanham Act § 45, 15 U.S.C. §1127 (2006). 
 121. Qualitex Co. v. Jacobson Products Co., Inc., 514 U.S. 159, 163 (1995). 
 122. Id. at 164. 
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A specific pattern or motif spliced into a synthetic DNA 
sequence could serve a trademark function if it identified the 
source of that DNA. To avoid the restrictions of the 
functionality doctrine, such a DNA trademark would best be 
placed outside of the coding (or functional) portion of the DNA 
sequence. Only human creativity would limit the patterns of 
nucleotides that synthetic biologists might choose to 
incorporate into a synthetic DNA sequence. To serve as an 
indicator of source, relevant consumers would have to recognize 
the pattern or motif intended to indicate source. Consumers of 
synthetic DNA sequences, however, would certainly scrutinize 
such sequences very carefully as a matter of course, and it 
would be difficult for them not to notice a DNA trademark. As 
the field of synthetic biology becomes more commercially 
important, DNA trademarks are likely to play increasingly 
important roles as indicators of source. 
IV.  OPEN SYNTHETIC BIOLOGY 
It has long been widely assumed that technological 
innovation was best spurred by either governmental funding or 
property-like incentives, such as patents and copyrights. The 
United States Constitution explicitly enables Congress “[t]o 
promote the Progress of Science and useful Arts, by securing 
for limited Times to Authors and Inventors the exclusive Right 
to their respective Writings and Discoveries.”123 However, the 
rise in importance of open source and free software, as well as 
insight into the phenomena of user, open, and collaborative 
innovation, has revealed an increasingly significant alternative 
to proprietary models of innovation. Within the field of 
synthetic biology, there are influential scientists, notably Drew 
Endy, Tom Knight, and Randy Rettberg, who have vigorously 
tried to push the field in the direction of open innovation. 
A.  OPEN INNOVATION 
Lawrence Lessig has noted that, although “[g]etting more 
progress is the constitutional aim of patents . . . the question 
that must always be asked of any patent regime is whether we 
have good reason to believe that patents have that effect.”124 
Lessig doubts the veracity of the traditional proprietary model 
                                                          
 123. U.S. CONST., art. I, § 8, cl. 8. 
 124. LAWRENCE LESSIG, THE FUTURE OF IDEAS 205 (2002). 
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of innovation, concluding instead that “[t]he strongest 
conclusion one can draw is that whatever benefit patents 
provide (except in industries such as pharmaceutics), it is 
small.”125 Eric von Hippel, the leading scholar on open and user 
innovation, is similarly dubious, noting that “[s]tudies find that 
innovators in many fields view patents as having only limited 
value.”126 Moreover, “most innovators do not judge patents to be 
very effective [in spurring innovation], and . . . the availability 
of patent grant protection does not appear to increase 
innovation investment in most fields.”127 Von Hippel has 
warned that, “with a few exceptions, innovators do not think 
that patents are very useful either for excluding imitators or for 
capturing royalties in most industries,”128 and that “the 
characteristics of present-day intellectual property regimes as 
actually experienced by innovators are far from the [beneficial] 
expectations of theorists and policy makers.”129 He notes a 
growing realization “that intellectual property rights are bad 
for innovation too in many cases.”130 
An increasing body of empirical research supports the 
hypothesis that intellectual property protection may harm, 
rather than spur, technological innovation. More than two 
decades ago, von Hippel reported that “empirical data seem to 
suggest that the patent grant has little value to innovators in 
most fields.”131 In 2004, Bessen and Hunt presented empirical 
evidence that, “on average, as firms’ investments in patent 
protection go up, their investments in research and 
development actually go down.”132 And, in their descriptively 
named book, Patent Failure, Bessen and Meurer offered the 
following observation: 
[I]t is not clear that the entry of imitators is necessarily detrimental 
to innovation as in the canonical reward theory model. If firms can 
obtain some rents even when competing against a limited number of 
                                                          
 125. Id. at 206. 
 126. ERIC VON HIPPEL, DEMOCRATIZING INNOVATION 10 (2005). 
 127. Id. at 112. 
 128. Id. at 84. 
 129. Id. at 112. 
 130. Id. 
 131. ERIC VON HIPPEL, THE SOURCES OF INNOVATION 48–51 (1988). 
 132. James Bessen & Robert M. Hunt, An Empirical Look at Software 
Patents (Federal Reserve Bank Of Philadelphia, Working Paper No. 03-17/R, 
2004). 
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other firms, then competition might actually increase innovation.133 
Their results “suggest that much innovation is not 
dependent on patenting.”134 They lament that “innovators have 
grown frustrated with the failings of the American patent 
system.”135 The authors also minimize the actual effect the 
patent system has on innovation, arguing “patents are neither 
the only nor even the most important means of encouraging 
innovation. On average, patents make a rather small 
contribution in this regard.”136 In 2009, an experimental study 
that directly compared proxies of innovation, productivity, and 
social utility in a patent system, a combination patent/open 
source system, and a commons, found that the commons 
outperformed the proprietary systems in every category 
examined, and by statistically significant amounts.137 
Moser has presented historical evidence showing that, at 
least during the nineteenth century, countries with patent 
systems did not experience significantly greater rates of 
technological innovation than countries without patent 
systems.138 The conclusion that Bessen and Meurer make is 
damning: 
Our empirical analysis indicates that the patent system provides 
little innovation incentive to most public firms; these are the firms 
that perform the lion’s share of R&D. So it seems unlikely that 
patents today are an effective policy instrument to encourage 
innovation overall.139 
Heller and Eisenberg have long suggested that too much 
patenting may result in an inefficient “tragedy of the 
anticommons.”140 Bessen and Meurer concur, noting that “our 
evidence implies that patents place a drag on innovation. 
Without this drag, the rate of innovation and technological 
progress might have been even greater, perhaps much 
                                                          
 133. JAMES BESSEN & MICHAEL J. MEURER, PATENT FAILURE: HOW 
JUDGES, BUREAUCRATS AND LAWYERS PUT INNOVATORS AT RISK 89 (2008). 
 134. Id. at 90. 
 135. Id. at 2. 
 136. Id. at 118. 
 137. Andrew W. Torrance & Bill Tomlinson, Patents and the Regress of 
Useful Arts, 10 COLUM. SCI. & TECH. L. REV. 131, 160–62 (2009). 
 138. Petra Moser, How Do Patent Laws Influence Innovation?  Evidence 
from Nineteenth-Century World Fairs 24–33 (NBER Working Paper Series, 
Working Paper No. 9909, 2002). 
 139. BESSEN & MEURER, supra note 133, at 216. 
 140. See, e.g., Heller & Eisenberg, Can Patents Deter Innovation? The 
Anticommons in Biomedical Research, 280 SCI. 698, 698–701 (1998). 
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greater.”141 Josh Lerner, conducting an empirical analysis of 
patent reforms in sixty countries over 150 years, even noted a 
modest negative correlation between the strengthening of a 
country’s patent system and patenting activity by domestic 
companies.142 
These results are inconsistent with the traditional 
assumption that the availability of intellectual property 
protection spurs technological innovation. Yochai Benkler have 
noted, however, that “[i]ncreasing patent 
protection . . . increases the costs that current innovators have 
to pay on existing knowledge more than it increases their 
ability to appropriate the value of their own contributions,”143 
and that patents may lower, rather than raise, rates of 
productivity.144 Yochai and Benkler have instead proposed that 
“commons-based strategies” may spur rates of innovation in 
fields such as software, agriculture, and drug development 
more than proprietary systems.145 Open biology and open 
synthetic biology represent non-proprietary modes of 
biotechnological innovation. 
B.  OPEN BIOLOGY 
There is a strong ethos in the nascent synthetic biology 
community in favor of maintaining open standards for and free 
availability of standardized biological parts. Although patent 
protection has traditionally been one of the economic pillars of 
the pharmaceutical and biotechnology industries, “open source 
biology” appears to be maintaining a strong lead over more 
proprietary approaches to synthetic biology innovation. One 
reason for this relative openness may be the academic 
backgrounds of some influential synthetic biologists. For 
example, the troika most responsible for the BBF and the 
iGEM competition came to the field biology from a background 
in engineering and computer science: Drew Endy received his 
undergraduate degree in civil engineering;146 Tom Knight is a 
                                                          
 141. BESSEN & MEURER, supra note 133, at 146. 
 142. YOCHAI BENKLER, THE WEALTH OF NETWORKS 39 (2006) (citing Josh 
Lerner, Patent Protection and Innovation Over 150 Years 2 (Nat’l Bureau Of 
Econ. Research, Working Paper No. 8977, 2002)). 
 143. YOCHAI BENKLER, THE WEALTH OF NETWORKS 39 (2006). 
 144. Id. at 49–50. 
 145. Id. at 317–55. 
 146. Mooallem, supra note 1, at 44. 
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Senior Scientist at the Massachusetts Institute of Technology 
(MIT) Computer Science and Artificial Intelligence 
Laboratory;147 and Randy Rettberg is an electrical engineer and 
computer scientist.148 The origins of the open source philosophy 
lie within the computer software community. 
Open source software differs markedly from proprietary 
software. Open source software involves “computer source code 
publicly available for licensees to use, modify, and redistribute, 
provided that these licensees make their enhancements 
available to others on the same terms.”149 The Open Source 
Initiative (OSI), a prominent institution in the open source 
community, has stated that software may qualify as open 
source if distributed under a license conforming to the Open 
Source Definition (OSD).150 Among the requirements of the 
OSD are free redistribution, availability of source code, free 
redistribution of derivative works, non-discrimination against 
potential users or fields of use, and technology neutrality.151 In 
an alternative conception proposed by Steven Weber, open 
source software must comply with three conditions: (1) “[the 
s]ource code must be distributed with the software or otherwise 
made available for no more than the cost of distribution,” (2) 
“[a]nyone may redistribute the software for free, without 
royalties or licensing fees to the author;” and (3) “[a]nyone may 
modify the software or derive other software from it, and then 
redistribute the modified software under the same terms.”152 
By any objective measure, open source software has been an 
influential and successful model for producing valuable 
software. The Linux operating system, the Apache web-server, 
and the mySQL database system all demonstrate the efficacy of 
the open source model of software design.153 
Biology has seen several previous attempts at using the 
open source approach. Led by biologist Richard Jefferson, 
                                                          
 147. Id. 
 148. Id. 
 149. Donna M. Gitter, Resolving the Open Source Paradox in 
Biotechnology: A Proposal for a Revised Open Source Policy for Publicly 
Funded Genomic Databases, 43 HOUS. L. REV. 1475, 1476 (2007). 
 150. Open Source Initiative, http://opensource.org/ (last visited Jan. 15, 
2010). 
 151. Id. 
 152. STEVEN WEBER, THE SUCCESS OF OPEN SOURCE 5 (2004). 
 153. Id. at 6. 
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CAMBIA (derived from the Spanish verb cambiar, meaning “to 
change”), a non-profit biotechnology research organization, 
began as an attempt to develop open source, instead of 
proprietary, biotechnology platforms for the genetic 
modification of crops that would avoid patent infringement.154 
CAMBIA’s BiOS (Biological Innovation for Open Society) 
initiative explicitly aimed to duplicate the success of non-
proprietary software development: 
Similar to the ethos of the Free Software movement, the BiOS 
Initiative is not about cheap or free stuff, either pharmaceuticals or 
food. It’s about creating the freedom to innovate based on what has 
come before, and the freedom to deliver the fruits of such innovation 
with few constraints.155 
The International HapMap Project (IHMP) represents 
another biological science initiative modeled after the successes 
of open source software. IMHP is a “partnership of scientists 
and funding agencies from Canada, China, Japan, Nigeria, the 
United Kingdom, and the United States to develop a public 
resource that will help researchers find genes associated with 
human disease and response to pharmaceuticals.”156 The 
HapMap (or map of haplotypes) “is a catalog of common genetic 
variants that occur in human beings.”157 The IHMP is 
attempting to create a public domain database of haplotypes by 
encouraging researchers not to patent their research, but, 
instead, to contribute their haplotype data freely to the IHMP 
genetic database. By “making this information freely available, 
the [IHMP] will help biomedical researchers find genes 
involved in disease and responses to therapeutic drugs.”158 
Researchers do not require licenses to gain access to the IHMP 
database, where data “can be downloaded with minimal 
                                                          
 154. Cambia – Enabling Innovation, 
http://www.cambia.org/daisy/cambia/home.html (last visited Feb. 26, 2010). 
 155. THE CAMBIA BIOS INITIATIVE, BIOLOGICAL INNOVATION FOR OPEN 
SOCIETY: IMPLEMENTATION PHASE 2006 – 2008 7 (2006), available at 
http://www.bios.net/daisy/bios/2029/version/default/part/ 
AttachmentData/data/BiOS%20Initiative%20Phase%202006-2008.pdf. 
 156. International HapMap Project Home Page, http://www.hapmap.org/ 
(last visited Feb. 26, 2010). 
 157. International HapMap Project, What is the HapMap?, 
http://hapmap.ncbi.nlm.nih.gov/whatishapmap.html.en (last visited Feb 26, 
2010). 
 158. International HapMap Project, About the HapMap, 
http://hapmap.ncbi.nlm.nih.gov/thehapmap.html.en (last visited Jan. 15, 
2010). 
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constraints.”159 Although one of the goals of the IHMP is to 
minimize hindrances on genetic research caused by patents, it 
does not oppose patents claiming haplotypes “as long as this 
action does not prevent others from obtaining access to data 
from the [IHMP].”160 
Another organization, the Tropical Diseases Initiative 
(TDI), has been organized around the principles of open source 
biology. The TDI was founded to spur medical research into 
treatments for tropical diseases that devastate poor and 
vulnerable populations in developing countries, focusing 
especially on diseases that have attracted little research and, 
as a result, development of fewer drugs to treat them.161 As 
with the IHMP, the TDI has acknowledged an important role 
for the patent system in spurring medical research, conceding 
that “patent incentives and commercial pharmaceutical houses 
have made Western health care the envy of the world.”162 
Furthermore, proponents of the TDI have lamented that “[t]o 
date, open-source methods have made little headway beyond 
software.”163 
C.  OPEN SYNTHETIC BIOLOGY 
In the realm of synthetic biology, two interrelated 
institutions have taken the lead in promoting the ethos of open 
biology: the BioBricks Foundation (BBF) and the iGEM 
competition. The BBF is a non-profit foundation founded by 
synthetic biologists at MIT, Harvard, and University of 
California, San Francisco.164 Its stated mission is to promote 
“the development and responsible use of technologies based on 
BioBrick™ standard DNA parts that encode basic biological 
functions.”165 Synthetic biologists and biological engineers can 
combine BioBricks inside living cells, in a manner analogous to 
combining pieces of Lego®, to “program living organisms in the 
                                                          
 159. Id. 
 160. International HapMap Project, Data Release Policy, 
http://hapmap.ncbi.nlm.nih.gov/datareleasepolicy.html.en (last visited Jan. 15, 
2010). 
 161. Stephen M. Maurer et al., Finding Cures for Tropical Diseases:  Is 
Open Source an Answer?, 1 PLOS MED. 183, 183 (2004). 
 162. Id. 
 163. Id. at 184. 
 164. The BioBricks Foundation, supra note 106. 
 165. Id. 
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same way a computer scientist can program a computer.”166 
The Registry is a repository for BioBricks and technical 
information about how to make and use BioBricks, currently 
housed at MIT.167 Anyone can contribute BioBricks to the 
Registry, but biologists are especially encouraged to ensure 
that any BioBricks submitted conform to BBF technical 
standards and are accompanied by sufficient information to 
enable their efficient and predictable use. The BBF “supports 
an open technical standards setting process that is used to 
define BioBrick™ standard biological parts, and other technical 
matters relevant to synthetic biology research and 
applications.”168 
Open synthetic biology represents a confluence of ideas 
from the open source software and open source biology 
movements, as well as the fields of biology, synthetic chemistry, 
engineering, and computer science. What makes it practicable 
is the distinctive chemical basis of heredity: genes. Genes are 
composed of deoxyribonucleic acid (“DNA”), a linear chain of 
deoxyribonucleotides (“nucleotides”) consisting of adenine (“A”), 
thymine (“T”), guanine (“G”), and cytosine (“C”). Genes are 
somewhat analogous to software algorithms. Their linear 
patterns of As, Ts, Gs, and Cs encode corresponding linear 
arrays of ribonucleotides. Some ribonucleotides perform direct 
metabolic functions within a cell, while most further encode 
linear arrays of amino acids, called polypeptides. Depending 
upon their particular nucleotide sequences, polypeptides may 
perform structural, signaling, or enzymatic functions within 
and between cells. Combinations of genes may encode groups of 
polypeptides that perform complicated functions, such as 
controlling cell division, immune response, or metabolic 
pathways. Although the  understanding of gene function is still 
in its infancy, most biologists assume that combinations of 
genes are also responsible, at least in part, for highly complex 
phenomena that take place at the level of the organism, such as 
locomotion, hibernation, reproduction, and behavior. 
Genes may be identified, characterized, isolated, and 
replicated. Their nucleotide sequences and genomic locations 
can be deliberately altered, or even inserted into novel host 
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 167. Id. 
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cells. Significantly, genes and chromosomes may also be 
designed from scratch, and then synthetically manufactured in 
large quantities. Just as a supplier of open source software 
might make its software easily available to anyone requesting 
it, the Registry makes BioBricks easily available to those 
conducting biological research or competing in the iGEM 
competition.169 And, as with open source software, the 
expectation is that those receiving BioBricks may further 
modify them structurally, or use arrays of BioBricks to achieve 
novel biological structures or functions, and then resubmit such 
modifications back into the Registry. 
D.  A CONSTITUTIONAL LICENSE FOR SYNTHETIC BIOLOGY 
Synthetic biology possesses a distinctively democratic 
character. From its foundation as a field, a core of influential 
synthetic biologists, notably Drew Endy, Tom Knight, and 
Randy Rettberg, as well as prominent institutions, such as the 
BBF, the Registry, and the iGEM competition, have been 
dedicated to ensuring that synthetic biology maintains its 
fundamentally open character. Each of the three stated goals of 
the BBF reflects this “open-source ethic:”170 (1) “to develop and 
implement legal strategies to ensure that BioBrick™ standard 
biological parts remain freely available to the public,”; (2) “to 
support the development of open technical standards that 
define BioBrick standard biological parts,” and (3) “to develop 
and provide educational and scientific materials to allow the 
public to use and improve existing BioBrick™ standard 
biological parts, and contribute new BioBrick™ standard 
biological parts.”171 
By supporting open technical standards and open standard 
setting, the BBF has attempted to define standards for 
BioBricks that others would follow. In fact, the tremendous 
success the BBF has experienced in amassing BioBricks in the 
Registry—more than 5,000 currently available for order by 
iGEM competition teams and academic laboratories172—has 
made the BBF influential on the rest of synthetic biology. 
                                                          
 169. iGEM 2007 Wiki Main Page,  
http://parts.mit.edu/igem07/index.php/Main_Page (last visited  Feb. 2, 2010). 
 170. Mooallem, supra note 1, at 45. 
 171. The BioBricks Foundation, supra note 106. 
 172. Registry, supra note 8. 
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There already exists a significant incentive for synthetic 
biologists to design their own DNA sequences to comply with 
BBF technical standards to ensure interoperability with the 
largest possible set of other DNA sequences. Network effects 
could drive the widespread, or even universal, adoption of BBF 
standards. 
Discouraging intellectual property protection for new 
BioBricks is more difficult. Some fear that excessive patenting 
of DNA sequences could act to discourage, or even stifle, 
biological research through what Eisenberg and Heller have 
called a “tragedy of the anticommons.”173 The experience of 
patents claiming human genes is often cited as a cautionary 
tale. Approximately twenty percent of all human genes were 
claimed in issued U.S. patents by 2005.174 Widespread 
patenting of human genes was described by some as a “gold 
rush.”175 Although empirical evidence has, thus far, cast doubt 
on the existence of a tragedy of the anticommons caused by 
human gene patents,176 proponents of open synthetic biology 
worry that their burgeoning field might be especially 
vulnerable to excessive patenting. Furthermore, as suggested 
earlier, synthetic DNA sequences may be especially easy to 
patent or copyright.177 
In an effort to manage challenges to synthetic biology 
posed by intellectual property, as well as to address other 
issues, such as biosafety, attribution, standards, and liability, 
the BBF has proposed The BioBrick™ Public Agreement, 
Version 1a (the “BioBrick Agreement”).178 The draft agreement, 
comprised of both The BioBrick™ Contributor Agreement 
(“Contributor Agreement”) and The BioBrick™ User 
Agreement (“User Agreement”), has been publicly posted on the 
BBF’s website in hopes of attracting support, comments, and 
suggestions. 
                                                          
 173. Heller & Eisenberg, supra note 140, at 698–701. 
 174. Kyle Jensen & Fiona Murray, Intellectual Property Landscape of the 
Human Genome, 310 SCI. 239, 239 (2005). 
 175. Tom Hollon, Gene Patent Revisions to Remove Some Controversies, 6 
NATURE MED. 362, 362 (2000). 
 176. Christopher M. Holman, The Impact of Human Gene Patents on 
Innovation and Access: A Survey of Human Gene Patent Litigation, 76 UMKC 
L. REV. 295, 353–54 (2007). 
 177. See supra Part III.A, III.B. 
 178. See infra Part VI; for a copy of the Agreement, see 
http://hdl.handle.net/1721.1/50999 (last visited May 12, 2010). 
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The first sentence in the Preface of both the Contributor 
and User Agreements begins with a broad statement of BBF’s 
mission and values: 
[The BBF] was established [1] to foster and advance innovation, 
research, standardization, and education in synthetic biology [2] 
through the open design, construction, distribution, understanding, 
and use of BioBrick™ compatible parts, namely standardized genetic 
materials and associated functional information, [3] in ways that 
benefit the world.179 
The Preface identifies three significant goals of the BBF. 
The first goal is to promote the development of the synthetic 
biology as a field. The word “standardization” signals the 
influence of an engineering approach, and a desire to avoid the 
messiness and unpredictability of traditional biological science. 
The second goal signals that, not only does the BBF 
promote the development of synthetic biology as a field of 
scientific endeavor, such development should adhere to 
principles of openness at every stage of development. Moreover, 
the adjective “open,” by modifying all of “design, construction, 
distribution, understanding, and use,” implies opposition to 
“closed” intellectual property protection.180 The Contributor and 
User Agreements both attempt to minimize the threats that 
patents and other forms of intellectual property might pose to 
achieving and maintaining an open model of synthetic biology. 
Section Three of the Contributor Agreement requires 
contributors not to assert any intellectual property rights they 
may have in BioBricks they contribute against the BBF or 
users. Thus, contributors provide assurance that users will 
have freedom to use contributed BioBricks. In Section Four, 
contributors must specifically identify any intellectual property 
rights that pertain to any BioBricks they contribute belonging 
to them or to third parties. The User Agreement contains a 
complementary Section Two, which requires users to 
acknowledge their awareness of contributors’ obligations under 
                                                          
 179. See infra Part VI, The BioBrick™ Public Agreement v1a, Preface. 
 180. However, note that the Preface later recognizes the possibility that 
some BioBricks may be encumbered by patent rights. The Contributor 
Agreement states: “Some such genetic materials may be subject to patents; 
some will not be. The patent-related provisions in this Contributor Agreement 
may or may not apply to the Materials” and the User Agreement states: “Some 
such genetic materials may be subject to patents; some will not be. The patent-
related provisions in this User Agreement may or may not apply to the 
Materials (as defined by one or more Contributors in their respective 
Contributor Agreements).” 
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Sections Three and Four of the Contributor Agreement. 
Consistent with the BBF’s ethos of openness, these provisions 
favor the use of full disclosure of information in light of the 
possible existence of patent rights relevant to the use of 
BioBricks. The full disclosure approach followed by the 
BioBrick Agreement raises two important issues. First, it is not 
obvious what incentives contributors would have to contribute 
their BioBricks, especially if they must effectively relinquish 
any intellectual property rights they may have in order to do 
so. Second, the BBF will have to decide how to proceed if third 
party intellectual property rights encumber a contributed 
BioBrick. Possible responses include not accepting the 
BioBrick, accepting the BioBrick but refusing to provide it to 
users, or simply assuming the risk that providing the BioBrick 
to users might trigger indirect infringement of any associated 
intellectual property rights. Although the BioBrick Agreement 
focuses on the use and contribution of BioBricks, the influence 
wielded by the BBF as the predominant—perhaps even 
dominant—source of synthetic biological building blocks has 
the potential to extend far beyond BioBricks per se. The use of 
“BioBrick™ compatible parts” in the BioBrick Agreement, 
rather than the logically more restrictive “BioBrick™ standard 
DNA parts” commonly used on the BBF website, further 
signals the ethos of openness that suffuses the BioBrick 
Agreement. 
The third goal flows from the modifying statement “in ways 
that benefit the world.”181 Concerns about biosafety surround 
not only the technologies being developed by synthetic biology 
but also the ethos of openness that pervades the field. 
Nightmare scenarios include “the malicious use of DNA 
sequences posted on the Internet to engineer a new virus or 
more devastating biological weapons.”182 Endy has noted that 
gene synthesis technology has already enabled the resurrection 
of the devastating 1918 influenza virus and could be used to 
produce genes of other dangerous pathogens.183  Whereas 
previous biotechnological advances have often been perceived 
as either subject to proprietary restrictions, or inaccessible to 
members of the public lacking requisite academic credentials or 
                                                          
 181. See infra Part VI, The BioBrick™ Public Agreement v1a, Preface. 
 182. Mooallem, supra note 1, at 45. 
 183. Endy, supra note 2, at 452. 
TORRANCE_MACROS_FINAL (DO NOT DELETE) 6/16/2010  2:16 PM 
662 MINN. J. L. SCI. & TECH. [Vol. 11:2 
 
 
access to expensive and secure laboratories, the openness of 
synthetic biology signals a democratization of access to its 
powerful technologies. Critics may worry that open access will 
not distinguish between beneficial and malicious users, and 
will thereby create the potential for biotechnological mischief 
by criminals, terrorists, hostile countries, or even careless 
biohackers. The Preface signals that only beneficial uses should 
be made of synthetic biology, though the very need to state this 
positive value indicates an awareness of its opposite. Section 
Seven of the Contributor Agreement and Section Four of the 
User Agreement both indirectly address biosafety by requiring 
that parties to the agreements comply with the laws in their 
jurisdiction. Obviously, such compliance is required regardless 
of the BioBrick Agreement. Section Five of the User 
Agreement, however, expressly requires users to “refrain from 
using the [BioBricks] in connection with any intentionally 
harmful, negligent, or unsafe uses.” 
The approach to biosafety taken by synthetic biology marks 
something of a departure from previous approaches the 
biological sciences have taken to manage risk and the 
perception of risk. Rather than restricting the technology to 
well-credentialed, institutionally-based scientists working in 
restricted-access laboratories, the ethos of synthetic biology 
demands a more open, democratic, and transparent approach. 
The BBF distributes kits of BioBricks to teams of 
undergraduates from all over the world. It encourages users to 
modify and combine BioBricks in novel ways, and then to share 
these modifications with the wider biological community. This 
spirit is more akin to computer hacker culture than to 
traditional biology. However, “[w]hat’s available to idealistic 
students, of course, would also be open to terrorists.”184 The 
BioBricks Agreement represents an attempt to address 
concerns about biosafety through contract, while 
simultaneously encouraging a degree of open access.  Such an 
approach is sure to engender criticism from those who fear the 
results of disseminating synthetic biological knowledge and 
materials; these concerns will likely grow in response to 
technical progress in this promising field of biology. However, a 
contrasting perspective doubts the feasibility of successfully 
restricting access to a technology as powerful, attractive, and 
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easy to engage in—even at home using inexpensive 
equipment185—as synthetic biology, and, instead, views 
openness as an advantage because it could provide a 
distributed network of many practitioners bound to notice and 
report malfeasance. 
A few additional aspects of the BioBrick Agreement are 
worth noting. Section Two of the Contributor Agreement 
requires contributors to agree to let the BBF insert a 
“BioBrick™ Identification Tag” into the DNA sequence of any 
contributed BioBrick. Users must make related promises in 
Section Three of the User Agreement, agreeing not to remove 
any “BioBrick™ Identification Tag” from a BioBrick and to 
ensure that the BioBrick Agreement logo is displayed 
prominently whenever a BioBrick, or modification thereof, is 
made available, commercialized, or distributed; Section Five of 
the Contributor Agreement informs contributors of this user 
obligation. This trademark policing is intended to ensure that 
BioBricks remain both standardized, compatible, and 
accessible. Finally, the BioBrick Agreement provides for 
attribution. Section Five of the Contributor Agreement allows 
contributors to request that users attribute BioBricks to their 
contributors when those users describe those BioBricks. Section 
Three of the User Agreement requires that users promise to 
make such attributions to contributors. 
The BioBrick Agreement may be viewed simply as a license 
agreement. By defining the obligations of contributors and 
users, it attempts to avoid ex ante disputes arising over 
ownership, intellectual property rights, attribution, and 
liability. Minimizing legal uncertainty may promote the growth 
of the Registry and the use of BioBricks. Like the open source 
and free software licenses that inspired it, however, the 
BioBrick Agreement may also be viewed in a more expansive 
light. Rather than a mere license, the BioBrick Agreement may 
be viewed as reflecting an initial effort to draft a legal 
constitution to guide the beneficial development of the field of 
synthetic biology. As with many other constitutions, the 
Preface articulates a number of value-laden, interpretive 
principles unnecessary to a mere license governing behavior 
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between two private actors. These principles—technological 
progress, openness, and beneficial uses—may represent the 
constitutional values of a field that aspires to more than 
efficient contracting and legal compliance. As Michael Specter 
recently suggested, “[t]he industrial age is drawing to a close, 
eventually to be replaced by an era of biological engineering.”186 
If synthetic biology realizes even a fraction of its potential, a 
clear articulation of constitutional values may prove much 
more valuable to development of the field than a license. 
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V.  CONCLUSIONS 
Synthetic biology aims to effect a paradigm shift in the 
biological sciences. If it is successful in importing engineering 
principles, such as standardization, decoupling, and 
abstraction, into the biological sciences, it may transform 
biology into a field in which it is routine to design and construct 
genes, proteins, metabolic pathways, cells, and whole 
organisms rapidly, inexpensively, and easily. Already, a 
number of institutions have helped synthetic biology achieve 
considerable success. The BBF and the Registry have 
successfully built a collection of thousands of BioBricks, and 
the iGEM competition has attracted participation from 
thousands of contestants, hundreds of teams, and dozens of 
countries. While the ethos of openness that pervades synthetic 
biology promises a democratization of biology, significant 
challenges to its openness still exist. The proprietary 
restrictions imposed by “closed” intellectual property create 
legal risk and uncertainty. Ironically, synthetic DNA sequences 
are likely more easily patentable and copyrightable than are 
DNA sequences derived from natural sources, thus creating the 
possibility that synthetic biology may increase, rather than 
decrease, intellectual property restrictions. Furthermore, 
concerns about biosafety may be exacerbated by open access to 
the products and methods of synthetic biology. To this end, the 
BBF has produced the BioBrick Agreement, a licensing 
framework intended to govern the legal relationships between 
the BBF, BioBricks contributors, and BioBricks users. The 
BioBrick Agreement has the potential to be more than a mere 
license. In fact, like a constitution, it could help define some of 
the foundational values and principles that synthetic biology 
might espouse to ensure that its social contributions prove 
beneficial to a degree commensurate with its scientific 
potential. 
 
